

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/588,568
				Filing Date	August 4, 2006
				First Named Inventor	Michael TESAR, et al.
				Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	4	Attorney Docket Number	49974-035USNATL

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US 2002/164788	11-7-2002	ELLIS, et al.	
	A2	US 2003/211553	11-13-2003	LOGTENBERG, et al.	
	A3	US 2004/141982	07/22/2004	MAYO	
	A4	US 5,545,405	08-13-1996	PAGE	
	A5	US 7,223,397	05-29-2007	ROSENBLUM, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code* Number* Kind Code ³ (if known)				
	B1	WO 02/6347 A	01-24-2002	CRUCELL, et al.		
	B2	WO 96/16990 A	06-06-1996	WELCOME FOUND [GB]		
	B3	EP 1 174 440 A	01-23-2002	BISYB B. V.		
	B4	WO 2006125640 A	11-30-2006	MORPHOSYS AG		
	B5	WO 2005103083 A2	11-03-2005	MORPHOSYS AG		
	B6	AU 8267501 A	01-30-2002	LOGTENBERG, et al.	See Corresponding US pub.	
	B7	EP 1720907 A2	11-15-2006	MORPHOSYS AG (DE)		
	B8	WO 02/32288	04-25-2002	TRUDEAU INST., INC.		
	B9	WO 05/087806	09-22-2005	BOEHRINGER INGELHEIM PHARM.		
	B10	WO 00/40265	07-13-2000	RESEARCH DEV. FOUNDATION		
	B11	WO 94/17184	08-04-1994	SCHERING CORP.		
	B12	WO 99/62526	12-09-1999	MAYO FOUNDATION		
	B13	WO 06/099875	09-28-2006	GENMAB A/S		
	B14	WO 05/042019	05-12-2005	UNIV. OF ROCHESTER		
	B15	WO 06/110581	10-19-2006	CHIRON CORP.		
	B16	WO 00/48361	08-17-2000	ISIS INNOV. LTD.		
	B17	WO 06/088951 A2	08-24-2006	TRUDEAU INST. INC.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/588,568
		Filing Date	August 4, 2006
		First Named Inventor	Michael TESAR, et al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 2	of 3	Attorney Docket Number	49974-035USNATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ANTONELLI, et al., "Human anti-CD38 autoantibodies raise intracellular calcium.."; Diabetes (2001) vol. 50; pp 985-991	
		AUSIELLO, et al., "Functional topography of discrete domains of human CD38"; Tissue Antigens, (2000); vol 56(6); pp 539-47	
		BOLLEN P., et al., "The Goettingen Minipig in pharmacology and toxicology"; Pharmacology and Toxicology, (1997); vol. 80; pp 3-4; XP009075772; ISSN 0901-9928	
		CHAMOW, et al., "Humanized, bispecific immunoadhesin-antibody that retargets"; J Immunol. (1994); vol1;153(9); pp 4268-80	
		DESHPANDE DEEPAK, et al., "Cloning and functional characterization of cDNA"; Faseb Journal; (2004); vol 18, No. 4-5; pp Abstr. 842.4 URL-http://www. XP009075817; ISSN 0892-6638	
		ELLIS, J., et al., "Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma"; Journal of Immunology; (1995); vol. 155, No. 2; pp 925-937; XP002146232	
		FERRERO E., et al., "Characterization and phylogenetic epitope mapping.."; BMC Immunology; (2004); vol. 5; pp 2004-09; XP002410155 ISSN: 1471-2172	
		FLAVELL, D., et al., "Therapy of human T-cell acute lymphoblastic leukaemia"; Br. J. Cancer; (2001); vol. 84; pp 571-578	
		FUNARO, A., et al., "Involvement of the multilineage CD38 molecule..." J. Immunol.; (1990); vol. 145; pp 2390-2396	
		HOSHINO S., et al., "Mapping of the catalytic and epitopic sites of human.." J. Immunol.; vol. 158 No. 2; pp 741-7	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/588,568
		Filing Date	August 4, 2006
		First Named Inventor	Michael TESAR, et al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	3	of	4
		Attorney Docket Number	49974-035USNATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JACKSON, D.G., et al., "Isolation of a cDNA encoding the human CD38 (T10)"; J. Immunol.; vol. 144 No. 7; pp 2811-5	
		KNAPPIK., et al., "Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular.."; J Mol Biol (2000); 296; pp 57-86	
		KONOPLEVA M., et al., "Ligation of cell surface CD38 protein with agonistic monoclonal.."; J. Immunol.; vol 161 No. (9); pp 4702-8	
		KREBS, B., et al., " High-throughput generation and engineering..."; J Immunol Methods (2001); vol 254; pp 67-84	
		LOHNING, C., et al., "Novel methods for displaying (poly) peptides/proteins on bacteriophage.." (2001); WO 01/05950	
		MALAVASI, F., et al., "Characterization of a murine monoclonal antibody.."; Hum. Immunol. (1984); vol 9; pp 9-20	
		MALONEY D., et al., "Antibody therapy for treatment of multiple myeloma"; Seminars in Hematology, (1999-01); pp 30-33; XP000857401 ISSN: 0037-1963	
		MARCHETTI, P., et al., "Prolonged in vitro exposure to autoantibodies against.."; Diabetes; vol 51; pp 474-477	
		MEHTA, K., et al., "Retinoic acid-induced CD38 antigen as a target for immunotoxin.."; Mol Cancer Ther (2004); vol 3; pp 345-352	
		NAMBA, M., et al., "Establishment of five human myeloma cell lines"; In vitro Cell Dev. Biol; (1989) vol 25; pp 723	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/588,568
		Filing Date	August 4, 2006
		First Named Inventor	Michael TESAR, et al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet 4	of 4	Attorney Docket Number	49974-035USNATL

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		NATA, K., et al., "Human gene encoding CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase)"; Gene (1997); vol 186, No. 2; pp 285-92	
		STEVENSON F. K., et al. "Preliminary Studies of an Immunotherapy Approach."; Blood, W.B. Saunders (1991); vol 77, No. 5; pp 1071-1079; XP000930093; ISSN 006-4971	
		ZHOU, H., et al., "Optimization of primer sequences for mouse scFv."; Nucleic Acids Res. (1994); vol 22; pp 888-889	
		ZOCCHI E., et al., "A single protein immunologically identified as CD38."; Biochemical and Biophysical Rsrch Comm. (1993); vol 196, No. 3; pp 1459-1465; XP 002410154 ISSN 0006	
		PNAS (1980), vol. 77; pp 1588	
		Third International Workshop on Human Leukocyte Differentiation Antigens, Oxford, England; September 1986	
		J Immunol (1990) vol 144; pp 2811	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.